Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04168502
Title Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Gruppo Italiano Malattie EMatologiche dell'Adulto
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST